MedTrace Logo

An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate

NCT00358722 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2009-08-10

No results posted yet for this study

Summary

Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.

The purpose of this study it to look at the safety of fermagate over longer periods of time.

Conditions

  • Chronic Kidney Failure

Interventions

DRUG

Fermagate

Film coated tablet 500mg

Sponsors & Collaborators

  • Ineos Healthcare Limited

    lead INDUSTRY

Principal Investigators

  • Simon Roe, MB ChB · Nottingham City Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358722 on ClinicalTrials.gov